A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The two co-primary objectives of this study are to assess in Japanese patients with severe
sepsis and/or septic shock: 1) the safety and tolerability of two different doses of
intravenous AZD9773 and 2) the PK of AZD9773.
The secondary objective is to make a preliminary assessment of the pharmacodynamics of two
different doses of intravenous AZD9773 in Japanese patients with severe sepsis and/or septic
shock.